X Wu
7 Papers
X Wu is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Benjamin Levy,Luiz Paz-Ares,Olivier Rixe,Wu Chou Su,Anthony W. Tolcher,Yanyan Lou,Yoshitaka Zenke,Panayiotis Savvides,E. Felip,Manuel Domine,Konstantinos Leventakos,Mariano Provencio Pulla,Marianna Koczywas,Atsushi Horiike,Sangita Rawat,X Wu,P. Basak,M J Chisamore,Yoshimitu Goto +18 more
TL;DR: In this article , Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed antibody-drug conjugate (ADC) that demonstrated encouraging efficacy and a manageable safety profile as monotherapy in patients with relapsed/refractory advanced/metastatic NSCLC.
19
883TiP A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Jason Chesney,Trisha Wise-Draper,Amod A. Sarnaik,F. Graf Finckenstein,Parameswaran Hari,Madan Jagasia,A. Desai,A. Suzuki,X Wu,Allison Betof Warner +9 more
TL;DR: IOV-4001 as mentioned in this paper is a TALEN-mediated PDCD-1 knockout autologous TIL cell therapy product, which has demonstrated efficacy in patients (pts) with advanced solid tumors, including melanoma.
6
The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment.
X Wu,R. Kumar,C. Milner-Watts,D. Walder,Nicolò Battisti,Anna Minchom,Jaishree Bhosle,Mary O'Brien +7 more
TL;DR: The G8 score with two cut-off values can predict functional status, chemotherapy tolerability and prognosis in older patients with lung cancer or mesothelioma, thus supporting oncologists on treatment decisions for this population as discussed by the authors .
1
EP16.01-025 Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
TL;DR: In this paper , the evolution of immune profile from primary non-small cell lung cancers (NSCLC) to metastases and the underlying molecular mechanisms, as well as the difference of immune evolution in local metastasis and distant metastasis is limited so far.
89P Novel resistance mechanisms to second-generation EGFR tyrosine kinase inhibitor afatinib in non-small cell lung cancer
Q. Ding,Yinghong Shao,X Wu,Qianqian Hu,Q. Meng,Jieying Yin,Qingqing Ou +6 more
TL;DR: In this paper , an irreversible pan-ErbB family inhibitor, Afatinib, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations.